Inhibikase Therapeutics Inc. held its Annual Meeting of Stockholders on June 27, 2025. At the meeting, two Class II directors, Amit Munshi and David Canner, Ph.D., were elected to the Board of Directors. The appointment of CohnReznick LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified. An amendment to the Company's 2020 Equity Incentive Plan to include an automatic "evergreen" provision and to extend the term of the plan was also approved.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inhibikase Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-152767), on June 30, 2025, and is solely responsible for the information contained therein.